Platelet sensitivity to a prostacyclin analogue in systemic sclerosis

J. J. F. Belch; A. O'Dowd; C. D. Forbes; R. D. Sturrock

doi:10.1093/rheumatology/24.4.346

Platelet sensitivity to a prostacyclin analogue in systemic sclerosis

J. J. F. Belch, A. O'Dowd, C. D. Forbes, R. D. Sturrock

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Vascular prostacyclin (PGI2) regulates platelet function and blood flow. In systemic sclerosis (SS) there is increased platelet aggregation (PA) but no information is available on the platelet/PGI2 relationship. We evaluated platelet sensitivity to a PGI2 analogue ZK36374 in 17 SS patients and 18 controls. The percentage (%) inhibition of PA was measured at two doses of ZK36374 with saline giving the 100% baseline. In the SS group 2 ng ZK36374 produced a percentage inhibition of 19 + 14 compared to a control value of 60 + 21, and 3 ng a percentage inhibition of 47 + 21 in the SS group and 82 + 20 in the controls. In 11 SS patients treated with either prostaglandin E or nifedipine the sensitivity approached normal. These data suggest that SS platelets are less sensitive to the inhibitory effect of PGI2 on PA. This may contribute to the vascular lesions of SS. Other cells are resistant to the effects of PGI2 and our findings support this picture of cellular resistance.

Original language	English
Pages (from-to)	346-350
Number of pages	5
Journal	Rheumatology
Volume	24
Issue number	4
DOIs	https://doi.org/10.1093/rheumatology/24.4.346
Publication status	Published - 1985

Access to Document

10.1093/rheumatology/24.4.346

Cite this

@article{b03265e5800a424bb31163f8cf8079ed,

title = "Platelet sensitivity to a prostacyclin analogue in systemic sclerosis",

abstract = "Vascular prostacyclin (PGI2) regulates platelet function and blood flow. In systemic sclerosis (SS) there is increased platelet aggregation (PA) but no information is available on the platelet/PGI2 relationship. We evaluated platelet sensitivity to a PGI2 analogue ZK36374 in 17 SS patients and 18 controls. The percentage (%) inhibition of PA was measured at two doses of ZK36374 with saline giving the 100% baseline. In the SS group 2 ng ZK36374 produced a percentage inhibition of 19 + 14 compared to a control value of 60 + 21, and 3 ng a percentage inhibition of 47 + 21 in the SS group and 82 + 20 in the controls. In 11 SS patients treated with either prostaglandin E or nifedipine the sensitivity approached normal. These data suggest that SS platelets are less sensitive to the inhibitory effect of PGI2 on PA. This may contribute to the vascular lesions of SS. Other cells are resistant to the effects of PGI2 and our findings support this picture of cellular resistance.",

author = "Belch, {J. J. F.} and A. O'Dowd and Forbes, {C. D.} and Sturrock, {R. D.}",

year = "1985",

doi = "10.1093/rheumatology/24.4.346",

language = "English",

volume = "24",

pages = "346--350",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Platelet sensitivity to a prostacyclin analogue in systemic sclerosis

AU - Belch, J. J. F.

AU - O'Dowd, A.

AU - Forbes, C. D.

AU - Sturrock, R. D.

PY - 1985

Y1 - 1985

N2 - Vascular prostacyclin (PGI2) regulates platelet function and blood flow. In systemic sclerosis (SS) there is increased platelet aggregation (PA) but no information is available on the platelet/PGI2 relationship. We evaluated platelet sensitivity to a PGI2 analogue ZK36374 in 17 SS patients and 18 controls. The percentage (%) inhibition of PA was measured at two doses of ZK36374 with saline giving the 100% baseline. In the SS group 2 ng ZK36374 produced a percentage inhibition of 19 + 14 compared to a control value of 60 + 21, and 3 ng a percentage inhibition of 47 + 21 in the SS group and 82 + 20 in the controls. In 11 SS patients treated with either prostaglandin E or nifedipine the sensitivity approached normal. These data suggest that SS platelets are less sensitive to the inhibitory effect of PGI2 on PA. This may contribute to the vascular lesions of SS. Other cells are resistant to the effects of PGI2 and our findings support this picture of cellular resistance.

AB - Vascular prostacyclin (PGI2) regulates platelet function and blood flow. In systemic sclerosis (SS) there is increased platelet aggregation (PA) but no information is available on the platelet/PGI2 relationship. We evaluated platelet sensitivity to a PGI2 analogue ZK36374 in 17 SS patients and 18 controls. The percentage (%) inhibition of PA was measured at two doses of ZK36374 with saline giving the 100% baseline. In the SS group 2 ng ZK36374 produced a percentage inhibition of 19 + 14 compared to a control value of 60 + 21, and 3 ng a percentage inhibition of 47 + 21 in the SS group and 82 + 20 in the controls. In 11 SS patients treated with either prostaglandin E or nifedipine the sensitivity approached normal. These data suggest that SS platelets are less sensitive to the inhibitory effect of PGI2 on PA. This may contribute to the vascular lesions of SS. Other cells are resistant to the effects of PGI2 and our findings support this picture of cellular resistance.

U2 - 10.1093/rheumatology/24.4.346

DO - 10.1093/rheumatology/24.4.346

M3 - Article

C2 - 2415199

SN - 1462-0324

VL - 24

SP - 346

EP - 350

JO - Rheumatology

JF - Rheumatology

IS - 4

ER -

Platelet sensitivity to a prostacyclin analogue in systemic sclerosis

Abstract

Access to Document

Fingerprint

Cite this